---
document_datetime: 2024-12-18 15:48:15
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/voncento-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: voncento-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.1419106
conversion_datetime: 2025-12-23 23:14:38.042122
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Voncento

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0066               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                       | 17/12/2024                          |                                             | PL                               |           |
| IG/1764              | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - | 26/06/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                |            |     |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0064   | B.I.c.z - Container closure system of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/05/2024 | n/a |           |
| IG/1714   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                         | 26/02/2024 | n/a |           |
| IB/0061   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                       | 09/01/2024 | n/a |           |
| WS/2503/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other | 09/11/2023 | n/a | variation |
| IG/1596   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                                                                                                                                                                                    | 20/02/2023 | n/a |           |

<div style=\"page-break-after: always\"></div>

|                     | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                     |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0058           | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                            | 01/12/2022 | n/a |                                   |
| IB/0056             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                     | 10/08/2022 | n/a |                                   |
| IB/0055             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                         | 28/04/2022 | n/a |                                   |
| PSUSA/10102 /202108 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                  | 07/04/2022 | n/a | PRAC Recommendation - maintenance |
| IG/1492             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 18/03/2022 | n/a |                                   |
| IB/0052/G           | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished           | 25/11/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0050   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                     | 19/11/2021 | 21/11/2022 | SmPC and PL | Section 6.3 in the SmPC and section 5 of the Package Leaflet have been updated. The information for local representatives in section 6 of the Product leaflet has also been updated and a linguistic correction is proposed to the French translation in section 4.6 |
| IG/1429   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                               | 20/08/2021 | n/a        |             |                                                                                                                                                                                                                                                                      |
| IA/0049   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                 | 22/06/2021 | n/a        |             |                                                                                                                                                                                                                                                                      |
| II/0047/G | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and | 15/04/2021 | n/a        |             |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IG/1356   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                      | 16/02/2021   | n/a   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0046   | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                         | 13/01/2021   | n/a   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0045   | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability                                                                                                                                                                                       | 03/12/2020   | n/a   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IG/1269   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                      | 15/07/2020   | n/a   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0042   | Submission of an updated RMP version 7 in order to: - align with the revision of the GVP module V - reflect the completion of the post-marketing study (PMS) in patients with Von Willebrand Disease (VWD) - request a waiver to the post-authorisation safety study (category 3 study) in patients with haemophilia A due to feasibility reasons. C.I.11.b - Introduction of, or change(s) to, the | 11/06/2020   | n/a   | The safety specifications of the RMP have been updated as part of this variation to align with the revised GVP module V, study CSLCT-BIO-12-83 in patients with Von Willebrand Disease (VWD) has been reflected as completed in the RMP. In addition, it was agreed to remove the post approval commitment to conduct the post-authorisation safety study Biostate_4001 in patients with haemophilia A. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|           | including the RMP - Implementation of which require to be further substantiated new additional data to be submitted by the MAH significant assessment is required                                                                                                                                      |            |     | authorisation, change(s) by where   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------|
| IG/1209   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                         | 25/02/2020 | n/a |                                     |
| II/0041/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation              | 12/09/2019 | n/a |                                     |
| IB/0040/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 27/05/2019 | n/a |                                     |
| IG/1074   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) -                                                                                                                                                 | 01/04/2019 | n/a |                                     |

<div style=\"page-break-after: always\"></div>

|                     | Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                                                                                                                                                                                                                                                        |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10102 /201808 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                                                                                                                                 | 14/03/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IB/0038             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                | 04/03/2019 | 28/02/2020 | SmPC and PL            |                                                                                                                                                                                                                                                                        |
| N/0037              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                              | 28/11/2018 | 28/02/2020 | PL                     |                                                                                                                                                                                                                                                                        |
| II/0035/G           | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products | 15/11/2018 | n/a        |                        |                                                                                                                                                                                                                                                                        |
| R/0032              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/02/2018 | 26/04/2018 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Voncento in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0034             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                    | 04/04/2018 | n/a        |                        |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                         |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------|
| PSUSA/10102 /201708 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/03/2018 | n/a        |             | PRAC Recommendation - maintenance                                                       |
| IG/0885             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/01/2018 | n/a        |             |                                                                                         |
| A31/0022            | Pursuant to Article 31 of Directive 2001/83/EC, Germany initiated a procedure on 6 July 2016 based on concerns resulting from the evaluation of data from pharmacovigilance activities. The PRAC was requested to assess the potential impact of the results of the SIPPET study (which concluded that recombinant factor VIII medicines had a higher incidence of inhibitor development than plasma-derived medicines), and to issue a recommendation as to whether the marketing authorisations of these products should be maintained, varied, suspended or revoked. The EMA concluded in September 2017 that there is no clear and consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: those derived from plasma and those made by recombinant DNA technology. Due to the different characteristics of individual products within the two classes, EMA concluded that the risk of inhibitor development | 14/09/2017 | 15/11/2017 | SmPC and PL | Please refer to the assessment report: human coagulation factor VIII - EMEA/H/A-31/1448 |

<div style=\"page-break-after: always\"></div>

|           | be evaluated individually for each medicine, regardless of class. The risk for each product will to be assessed as more evidence becomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        | should continue available.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------|
| II/0017/G | This was an application for a group of variations. Sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC have been updated to reflect the final clinical study data from study CSLCT-BIO-08-53 (a phase III, open-Label, multicentre study to evaluate efficacy, pharmacokinetics, and safety in paediatric subjects with haemophilia A) to the Guideline on the SPC (European Commission 'Notice to Applicants') in accordance to the EMA guideline on the Core SPC for human plasma derived and recombinant coagulation factor VIII products (CPMP/BPWG/1619/99 Rev.1 December 2012). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 22/06/2017 | 25/07/2017 | SmPC and PL            |                              |
| IB/0029   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/07/2017 | 15/11/2017 | SmPC, Labelling and PL |                              |

<div style=\"page-break-after: always\"></div>

| IG/0788             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                     | 12/04/2017   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027             | B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number                                                                                                                                                          | 22/03/2017   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10102 /201608 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                      | 09/03/2017   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                          |
| IG/0757             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                     | 26/01/2017   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0021/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or | 10/11/2016   | 25/07/2017 | SmPC | As a consequence of the change in assay for vWF from a Ristocetin Cofactor assay to an Activity assay that was the subject of this variation, a minor editorial change to the Voncento SmPC was made in order to change the reference to the Ristocetin Cofactor (RCo) assay in the footnote in Section 2 - 'Qualitative And Quantitative Composition' by removing the abbreviation 'RCo'. |

<div style=\"page-break-after: always\"></div>

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10102 /201602 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/09/2016 | n/a | PRAC Recommendation - maintenance |
| IA/0023/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/08/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------|
| IA/0024/G | for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/08/2016 | n/a | This was an application |
| IG/0676/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier | 27/04/2016 | n/a |                         |

<div style=\"page-break-after: always\"></div>

|                     | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                       |            |            |                                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10102 /201508 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                    | 17/03/2016 | n/a        |                                  | PRAC Recommendation - maintenance |
| PSUSA/10102 /201502 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                    | 10/09/2015 | n/a        |                                  | PRAC Recommendation - maintenance |
| IA/0016/G           | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                       | 31/07/2015 | n/a        |                                  |                                   |
| II/0008/G           | This was an application for a group of variations. Extension of indication to include prophylactic treatment of patients with Von Willebrand Disease (VWD); in addition, the product information has been updated to provide data on the treatment of paediatric patients with VWD. As a consequence, sections 4.1, 4.2, 4.4, 4.9, 5.1 and 5.2 of the SmPC have been updated. The package leaflet is updated accordingly. Moreover, the MAH took the opportunity to correct the manufacturing sites addresses in | 25/06/2015 | 31/07/2015 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | make editorial changes to the product information. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     | Annex II and to   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IA/0015/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 06/07/2015 | n/a |                   |
| IAIN/0013 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/04/2015 | n/a |                   |

<div style=\"page-break-after: always\"></div>

|                     | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10102 /201408 | Periodic Safety Update EU Single assessment - human coagulation factor viii / human von willebrand factor (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/03/2015 | n/a        |             | PRAC Recommendation - maintenance |
| IA/0012             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/01/2015 | n/a        |             |                                   |
| IA/0011/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation | 08/12/2014 | 05/05/2015 | Annex II    |                                   |
| IAIN/0009           | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                                       | 04/11/2014 | 05/05/2015 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

| PSUV/0007   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/09/2014   | n/a        |      | PRAC Recommendation - maintenance   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------------|
| IB/0004/G   | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the | 22/05/2014   | n/a        |      |                                     |
| IB/0006     | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                           | 04/04/2014   | 05/05/2015 | SmPC |                                     |
| IAIN/0005   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                | 28/02/2014   | n/a        |      |                                     |
| IAIN/0003   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                               | 18/11/2013   | n/a        |      |                                     |

<div style=\"page-break-after: always\"></div>

| IB/0001     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                   | 14/11/2013   | n/a   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IAIN/0002/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure | 27/09/2013   | n/a   |